Presynaptic effects of levodopa and their possible role in dyskinesia

Mov Disord. 2015 Jan;30(1):45-53. doi: 10.1002/mds.26103. Epub 2014 Dec 1.

Abstract

Levodopa replacement therapy has long provided the most effective treatment for Parkinson's disease (PD). We review how this dopamine (DA) precursor enhances dopaminergic transmission by providing a greater sphere of neurotransmitter influence as a result of the confluence of increased quantal size and decreased DA reuptake, as well as loading DA as a false transmitter into surviving serotonin neuron synaptic vesicles. We further review literature on how presynaptic dysregulation of DA release after l-dopa might trigger dyskinesias in PD patients.

Keywords: Parkinson's Disease; dopamine; dyskinesia; levodopa; presynaptic; serotonin.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Dopamine / metabolism
  • Dopamine Agents / adverse effects*
  • Dyskinesia, Drug-Induced* / etiology
  • Dyskinesia, Drug-Induced* / metabolism
  • Dyskinesia, Drug-Induced* / pathology
  • Humans
  • Levodopa / adverse effects*
  • Neurons / cytology*
  • Neurons / drug effects
  • Parkinson Disease / drug therapy
  • Presynaptic Terminals / drug effects*
  • Presynaptic Terminals / metabolism

Substances

  • Dopamine Agents
  • Levodopa
  • Dopamine